A citation-based method for searching scientific literature

Munir Pirmohamed, Girvan Burnside, Niclas Eriksson, Andrea L Jorgensen, Cheng Hock Toh, Toby Nicholson, Patrick Kesteven, Christina Christersson, Bengt Wahlström, Christina Stafberg, J Eunice Zhang, Julian B Leathart, Hugo Kohnke, Anke H Maitland-van der Zee, Paula R Williamson, Ann K Daly, Peter Avery, Farhad Kamali, Mia Wadelius. N Engl J Med 2013
Times Cited: 547







List of co-cited articles
795 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A pharmacogenetic versus a clinical algorithm for warfarin dosing.
Stephen E Kimmel, Benjamin French, Scott E Kasner, Julie A Johnson, Jeffrey L Anderson, Brian F Gage, Yves D Rosenberg, Charles S Eby, Rosemary A Madigan, Robert B McBane,[...]. N Engl J Med 2013
505
58

Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
Brian F Gage, Anne R Bass, Hannah Lin, Scott C Woller, Scott M Stevens, Noor Al-Hammadi, Juan Li, Tomás Rodríguez, J Philip Miller, Gwendolyn A McMillin,[...]. JAMA 2017
127
41

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
J A Johnson, K E Caudle, L Gong, M Whirl-Carrillo, C M Stein, S A Scott, M T Lee, B F Gage, S E Kimmel, M A Perera,[...]. Clin Pharmacol Ther 2017
255
36

Estimation of the warfarin dose with clinical and pharmacogenetic data.
T E Klein, R B Altman, N Eriksson, B F Gage, S E Kimmel, M-T M Lee, N A Limdi, D Page, D M Roden, M J Wagner,[...]. N Engl J Med 2009
32

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
B F Gage, C Eby, J A Johnson, E Deych, M J Rieder, P M Ridker, P E Milligan, G Grice, P Lenzini, A E Rettie,[...]. Clin Pharmacol Ther 2008
547
28

CYP4F2 genetic variant alters required warfarin dose.
Michael D Caldwell, Tarif Awad, Julie A Johnson, Brian F Gage, Mat Falkowski, Paul Gardina, Jason Hubbard, Yaron Turpaz, Taimour Y Langaee, Charles Eby,[...]. Blood 2008
380
16

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
Minoli A Perera, Larisa H Cavallari, Nita A Limdi, Eric R Gamazon, Anuar Konkashbaev, Roxana Daneshjou, Anna Pluzhnikov, Dana C Crawford, Jelai Wang, Nianjun Liu,[...]. Lancet 2013
172
15

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
J A Johnson, L Gong, M Whirl-Carrillo, B F Gage, S A Scott, C M Stein, J L Anderson, S E Kimmel, M T M Lee, M Pirmohamed,[...]. Clin Pharmacol Ther 2011
426
15

The largest prospective warfarin-treated cohort supports genetic forecasting.
Mia Wadelius, Leslie Y Chen, Jonatan D Lindh, Niclas Eriksson, Mohammed J R Ghori, Suzannah Bumpstead, Lennart Holm, Ralph McGinnis, Anders Rane, Panos Deloukas. Blood 2009
406
15

Pharmacogenomics in the clinic.
Mary V Relling, William E Evans. Nature 2015
371
14

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Nita A Limdi, Mia Wadelius, Larisa Cavallari, Niclas Eriksson, Dana C Crawford, Ming-Ta M Lee, Chien-Hsiun Chen, Alison Motsinger-Reif, Hersh Sagreiya, Nianjun Liu,[...]. Blood 2010
262
14

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Jessica L Mega, Joseph R Walker, Christian T Ruff, Alexander G Vandell, Francesco Nordio, Naveen Deenadayalu, Sabina A Murphy, James Lee, Michele F Mercuri, Robert P Giugliano,[...]. Lancet 2015
115
14

A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
Talitha I Verhoef, Georgia Ragia, Anthonius de Boer, Rita Barallon, Genovefa Kolovou, Vana Kolovou, Stavros Konstantinides, Saskia Le Cessie, Efstratios Maltezos, Felix J M van der Meer,[...]. N Engl J Med 2013
165
14

Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients.
Sheng-Wen Huang, Hai-Sheng Chen, Xian-Qun Wang, Ling Huang, Ding-Li Xu, Xiao-Jia Hu, Zhi-Hui Huang, Yong He, Kai-Ming Chen, Dao-Kang Xiang,[...]. Pharmacogenet Genomics 2009
122
12

SLCO1B1 variants and statin-induced myopathy--a genomewide study.
E Link, S Parish, J Armitage, L Bowman, S Heath, F Matsuda, I Gut, M Lathrop, R Collins. N Engl J Med 2008
11

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.
C H van der Wouden, A Cambon-Thomsen, E Cecchin, K C Cheung, C L Dávila-Fajardo, V H Deneer, V Dolžan, M Ingelman-Sundberg, S Jönsson, M O Karlsson,[...]. Clin Pharmacol Ther 2017
138
11


Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
Mark J Rieder, Alexander P Reiner, Brian F Gage, Deborah A Nickerson, Charles S Eby, Howard L McLeod, David K Blough, Kenneth E Thummel, David L Veenstra, Allan E Rettie. N Engl J Med 2005
11

Genetic and clinical factors relating to warfarin dosing.
Daniel E Jonas, Howard L McLeod. Trends Pharmacol Sci 2009
95
11

A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).
Jeffrey L Anderson, Benjamin D Horne, Scott M Stevens, Scott C Woller, Kent M Samuelson, Justin W Mansfield, Michelle Robinson, Stephanie Barton, Kim Brunisholz, Chrissa P Mower,[...]. Circulation 2012
165
11

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
Elizabeth A Sconce, Tayyaba I Khan, Hilary A Wynne, Peter Avery, Louise Monkhouse, Barry P King, Peter Wood, Patrick Kesteven, Ann K Daly, Farhad Kamali. Blood 2005
676
11

A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI.
Daniel M F Claassens, Gerrit J A Vos, Thomas O Bergmeijer, Renicus S Hermanides, Arnoud W J van 't Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, Richard M Tjon Joe Gin, Folkert W Asselbergs,[...]. N Engl J Med 2019
182
11

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
S A Scott, K Sangkuhl, C M Stein, J-S Hulot, J L Mega, D M Roden, T E Klein, M S Sabatine, J A Johnson, A R Shuldiner. Clin Pharmacol Ther 2013
555
10

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, Chris Barnes, Niclas Eriksson, Nicole Soranzo, Pamela Whittaker, Venkatesh Ranganath, Vasudev Kumanduri, William McLaren,[...]. PLoS Genet 2009
450
10

Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
Henry M Dunnenberger, Kristine R Crews, James M Hoffman, Kelly E Caudle, Ulrich Broeckel, Scott C Howard, Robert J Hunkler, Teri E Klein, William E Evans, Mary V Relling. Annu Rev Pharmacol Toxicol 2015
262
10



Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial.
Nicholas L Syn, Andrea Li-Ann Wong, Soo-Chin Lee, Hock-Luen Teoh, James Wei Luen Yip, Raymond Cs Seet, Wee Tiong Yeo, William Kristanto, Ping-Chong Bee, L M Poon,[...]. BMC Med 2018
19
52

Oral anticoagulation: a critique of recent advances and controversies.
Munir Pirmohamed, Farhad Kamali, Ann K Daly, Mia Wadelius. Trends Pharmacol Sci 2015
50
20

National Trends in Ambulatory Oral Anticoagulant Use.
Geoffrey D Barnes, Eleanor Lucas, G Caleb Alexander, Zachary D Goldberger. Am J Med 2015
371
10

Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.
Innocent G Asiimwe, Eunice J Zhang, Rostam Osanlou, Amanda Krause, Chrisly Dillon, Guilherme Suarez-Kurtz, Honghong Zhang, Jamila A Perini, Jessicca Y Renta, Jorge Duconge,[...]. Clin Pharmacol Ther 2020
18
55

Genetic and clinical predictors of warfarin dose requirements in African Americans.
L H Cavallari, T Y Langaee, K M Momary, N L Shapiro, E A Nutescu, W A Coty, M A G Viana, S R Patel, J A Johnson. Clin Pharmacol Ther 2010
145
9

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Larisa H Cavallari, Craig R Lee, Amber L Beitelshees, Rhonda M Cooper-DeHoff, Julio D Duarte, Deepak Voora, Stephen E Kimmel, Caitrin W McDonough, Yan Gong, Chintan V Dave,[...]. JACC Cardiovasc Interv 2018
142
9

Warfarin pharmacogenetics.
Julie A Johnson, Larisa H Cavallari. Trends Cardiovasc Med 2015
83
10

Pharmacogenetic dosing of warfarin in the Han-Chinese population: a randomized trial.
Ming-Shien Wen, Kuan-Cheng Chang, Tsong-Hai Lee, Ying-Fu Chen, Kuo-Chun Hung, Yeu-Jhy Chang, Chia-Wei Liou, Jin-Jer Chen, Chien-Hung Chang, Chao-Yung Wang,[...]. Pharmacogenomics 2017
22
40

A method to determine the optimal intensity of oral anticoagulant therapy.
F R Rosendaal, S C Cannegieter, F J van der Meer, E Briët. Thromb Haemost 1993
9

Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study.
Andrea L Jorgensen, Clare Prince, Gail Fitzgerald, Anita Hanson, Jennifer Downing, Julia Reynolds, J Eunice Zhang, Ana Alfirevic, Munir Pirmohamed. BMC Med 2019
19
47


Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese.
Pei-Chieng Cha, Taisei Mushiroda, Atsushi Takahashi, Michiaki Kubo, Shiro Minami, Naoyuki Kamatani, Yusuke Nakamura. Hum Mol Genet 2010
100
8

Genetic determinants of response to warfarin during initial anticoagulation.
Ute I Schwarz, Marylyn D Ritchie, Yuki Bradford, Chun Li, Scott M Dudek, Amy Frye-Anderson, Richard B Kim, Dan M Roden, C Michael Stein. N Engl J Med 2008
422
8


Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
Simone Rost, Andreas Fregin, Vytautas Ivaskevicius, Ernst Conzelmann, Konstanze Hörtnagel, Hans-Joachim Pelz, Knut Lappegard, Erhard Seifried, Inge Scharrer, Edward G D Tuddenham,[...]. Nature 2004
784
8

HLA-B*5701 screening for hypersensitivity to abacavir.
Simon Mallal, Elizabeth Phillips, Giampiero Carosi, Jean-Michel Molina, Cassy Workman, Janez Tomazic, Eva Jägel-Guedes, Sorin Rugina, Oleg Kozyrev, Juan Flores Cid,[...]. N Engl J Med 2008
8

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.
Hsiang-Yu Yuan, Jin-Jer Chen, M T Michael Lee, Ju-Chieh Wung, Ying-Fu Chen, Min-Ji Charng, Ming-Jen Lu, Chi-Ren Hung, Chun-Yu Wei, Chien-Hsiun Chen,[...]. Hum Mol Genet 2005
361
8

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Manesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, Guohua Pan, Daniel E Singer, Werner Hacke, Günter Breithardt, Jonathan L Halperin, Graeme J Hankey, Jonathan P Piccini,[...]. N Engl J Med 2011
8

Dabigatran versus warfarin in patients with atrial fibrillation.
Stuart J Connolly, Michael D Ezekowitz, Salim Yusuf, John Eikelboom, Jonas Oldgren, Amit Parekh, Janice Pogue, Paul A Reilly, Ellison Themeles, Jeanne Varrone,[...]. N Engl J Med 2009
8

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Mitchell K Higashi, David L Veenstra, L Midori Kondo, Ann K Wittkowsky, Sengkeo L Srinouanprachanh, Fred M Farin, Allan E Rettie. JAMA 2002
785
8

Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Kelly E Caudle, Henry M Dunnenberger, Robert R Freimuth, Josh F Peterson, Jonathan D Burlison, Michelle Whirl-Carrillo, Stuart A Scott, Heidi L Rehm, Marc S Williams, Teri E Klein,[...]. Genet Med 2017
226
7


Pharmacogenomics knowledge for personalized medicine.
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin Pharmacol Ther 2012
956
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.